Balyasny Asset Management
ALXN

Balyasny Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Balyasny Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-771,620
Closed -$142M – 2659
2021
Q2 		$142M Sell
771,620
-28,724
-4% -$4.93M 0.67% 14
2021
Q1 		$122M Buy
800,344
+470,542
+143% +$72.8M 0.6% 16
2020
Q4 		$51.5M Buy
329,802
+13,774
+4% +$1.77M 0.29% 75
2020
Q3 		$36.2M Buy
316,028
+169,506
+116% +$18.3M 0.27% 82
2020
Q2 		$16.4M Buy
146,522
+50,303
+52% +$5.34M 0.14% 215
2020
Q1 		$8.64M Sell
96,219
-220,280
-70% -$21.6M 0.1% 272
2019
Q4 		$34.2M Buy
316,499
+314,169
+13,484% +$33.6M 0.2% 143
2019
Q3 		$228K Sell
2,330
-43,347
-95% -$4.89M ﹤0.01% 1067
2019
Q2 		$5.98M Sell
45,677
-82,921
-64% -$10.7M 0.04% 544
2019
Q1 		$17.4M Sell
128,598
-256,347
-67% -$31.9M 0.12% 253
2018
Q4 		$37.5M Buy
384,945
+73,144
+23% +$8.65M 0.27% 95
2018
Q3 		$43.3M Buy
311,801
+160,733
+106% +$20.2M 0.2% 131
2018
Q2 		$18.8M Sell
151,068
-370,070
-71% -$43.3M 0.09% 327
2018
Q1 		$58.1M Sell
521,138
-704,352
-57% -$84.2M 0.24% 92
2017
Q4 		$147M Buy
1,225,490
+1,052,546
+609% +$128M 0.46% 31
2017
Q3 		$24.3M Sell
172,944
-15,286
-8% -$2.08M 0.1% 286
2017
Q2 		$22.9M Buy
188,230
+105,071
+126% +$12.2M 0.09% 289
2017
Q1 		$10.1M Sell
83,159
-130,741
-61% -$16.9M 0.05% 487
2016
Q4 		$26.2M Buy
213,900
+42,168
+25% +$5.16M 0.14% 208
2016
Q3 		$21M Buy
171,732
+72,669
+73% +$9.35M 0.12% 236
2016
Q2 		$11.6M Buy
99,063
+9,177
+10% +$1.3M 0.07% 319
2016
Q1 		$12.5M Buy
89,886
+45,948
+105% +$6.75M 0.07% 343
2015
Q4 		$8.38M Buy
+43,938
New +$7.68M 0.06% 400
2015
Q3 		– Sell
-35,000
Closed -$6.33M – 1466
2015
Q2 		$6.33M Sell
35,000
-91,681
-72% -$15.8M 0.04% 529
2015
Q1 		$22M Buy
+126,681
New +$22.9M 0.18% 178
2014
Q3 		– Sell
-26,400
Closed -$4.13M – 899
2014
Q2 		$4.13M Buy
+26,400
New +$4.17M 0.05% 416

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Balyasny Asset Management's ALXN Position: Q3 2021 in Review

Balyasny Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 771,620 shares — an estimated $142M sold.

Balyasny Asset Management first reported a position in ALXN in Q2 2014 and held it in 26 quarters. The position peaked at $147M in Q4 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Balyasny Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 771,620 Alexion Pharmaceuticals shares in Q3 2021, an estimated $142M.
  • Balyasny Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 26 quarters.
  • Balyasny Asset Management's Alexion Pharmaceuticals position peaked at $147M in Q4 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Balyasny Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.